Resistance to antiretroviral agents in individuals with HIV-1 non-B subtypes.

Abstract:

:Naturally occurring polymorphisms at positions involved in resistance to antiretroviral agents are frequently seen in HIV-1 non-B subtypes. Although they do not seem to affect significantly the susceptibility to antiretroviral drugs in vitro, they may facilitate the selection of different pathways and/or a more rapid emergence of drug resistance and treatment failure under not fully suppressive treatment regimens.

journal_name

HIV Clin Trials

journal_title

HIV clinical trials

authors

Holguín A,Soriano V

doi

10.1310/7bwp-0x7f-nxna-qrnp

keywords:

subject

Has Abstract

pub_date

2002-09-01 00:00:00

pages

403-11

issue

5

eissn

1528-4336

issn

1945-5771

journal_volume

3

pub_type

杂志文章,评审
  • Low-dose daily subcutaneous interleukin-2 in combination with highly active antiretroviral therapy in HIV+ patients: a randomized controlled trial.

    abstract:PURPOSE:Previous studies with intermittent interleukin-2 (IL-2) therapy using intermediate and high levels of IL-2 have demonstrated significant increases in the CD4 + T cell count in HIV-infected patients. Intermittent regimens are amenable to outpatient use, but severe adverse events are frequently experienced with i...

    journal_title:HIV clinical trials

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1310/T5FR-8JPX-0NEF-XDKD

    authors: Lalezari JP,Beal JA,Ruane PJ,Cohen CJ,Jacobson EL,Sundin D,Leong WP,Raffanti SP,Wheeler DA,Anderson RD,Keiser P,Schrader SR,Goodgame JC,Steinhart CR,Murphy RL,Wolin MJ,Smith KA

    更新日期:2000-11-01 00:00:00

  • Factors associated with complete adherence to HIV combination antiretroviral therapy.

    abstract:PURPOSE:To assess factors associated with adherence, particularly pill burden, to combination antiretroviral therapy (cART) using multivariate models. METHOD:A cross-sectional survey of US adults with a self-reported diagnosis of HIV/AIDS was conducted between April and May 2007. Respondents on a cART regimen of at le...

    journal_title:HIV clinical trials

    pub_type: 杂志文章

    doi:10.1310/hct1202-71

    authors: Juday T,Gupta S,Grimm K,Wagner S,Kim E

    更新日期:2011-03-01 00:00:00

  • Cerebral function in perinatally HIV-infected young adults and their HIV-uninfected sibling controls.

    abstract:BACKGROUND:Perinatally acquired HIV-infected (PaHIV) young adults undergo neurodevelopment in the presence of HIV infection and antiretroviral therapy, which may lead to neurocognitive (NC) impairment. Knowledge of NC function in this group is sparse and control data lacking. We compared cerebral function in young adul...

    journal_title:HIV clinical trials

    pub_type: 杂志文章

    doi:10.1179/1528433614Z.0000000003

    authors: Ashby J,Foster C,Garvey L,Wan T,Allsop J,Paramesparan Y,Taylor-Robinson SD,Fidler S,Winston A

    更新日期:2015-03-01 00:00:00

  • Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies.

    abstract:OBJECTIVES:Week 96 efficacy and safety of the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine (RPV) was compared to efavirenz (EFV) in subset of 1,096 subjects who received emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in pooled data from 2 phase 3 studies. METHODS:ECHO and THRIVE are double...

    journal_title:HIV clinical trials

    pub_type: 杂志文章,随机对照试验

    doi:10.1310/hct1403-81

    authors: Nelson MR,Elion RA,Cohen CJ,Mills A,Hodder SL,Segal-Maurer S,Bloch M,Garner W,Guyer B,Williams S,Chuck S,Vanveggel S,Deckx H,Stevens M

    更新日期:2013-05-01 00:00:00

  • Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers.

    abstract:PURPOSE:To characterize the steady-state pharmacokinetic combination of the nonpeptidic protease inhibitor tipranavir (TPV) with ritonavir (RTV) in 95 healthy adult volunteers, a phase 1, single-center, open-label, randomized, parallel-group trial was conducted. METHOD:Participants received 250-mg self-emulsifying dru...

    journal_title:HIV clinical trials

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1310/RRX7-49ME-27V7-MWWV

    authors: MacGregor TR,Sabo JP,Norris SH,Johnson P,Galitz L,McCallister S

    更新日期:2004-11-01 00:00:00

  • Telmisartan increases vascular reparative capacity in older HIV-infected adults: a pilot study.

    abstract:BACKGROUND:Endothelial progenitor cells (EPCs) are bone marrow-derived cells that contribute to vascular repair. EPCs may be reduced in HIV-infected (HIV+) persons, contributing to cardiovascular disease (CVD). Telmisartan is an angiotensin receptor blocker that increases EPCs in HIV-uninfected adults. OBJECTIVE:To as...

    journal_title:HIV clinical trials

    pub_type: 杂志文章

    doi:10.1080/15284336.2016.1234222

    authors: Lake JE,Seang S,Kelesidis T,Currier JS,Yang OO

    更新日期:2016-11-01 00:00:00

  • The insufficient suppression of viral load by saquinavir hard gel is reversible: a retrospective cohort study.

    abstract:PURPOSE:To assess the effect of changing antiretroviral therapy in patients initially treated with saquinavir hard gel capsule (hgc). METHOD:A retrospective cohort study comparing the virological and immunological responses in antiretroviral-naïve patients initially treated with a regimen of saquinavir-hgc, zidovudine...

    journal_title:HIV clinical trials

    pub_type: 临床试验,杂志文章

    doi:10.1310/KED4-8TW3-4ARG-HFC5

    authors: Jensen-Fangel S,Kirk O,Blaxhult A,Gerstoft J,Pedersen C,Black FT,Lundgren JD,Obel N

    更新日期:2001-03-01 00:00:00

  • Site nurse-initiated adherence and symptom support telephone calls for HIV-positive individuals starting antiretroviral therapy, ACTG 5031: substudy of ACTG 384.

    abstract:BACKGROUND:Effective and easy to implement interventions to improve adherence to antiretroviral therapy are needed. OBJECTIVE:To compare site nurse-initiated adherence and symptom support telephone calls for HIV-positive individuals starting antiretroviral therapy to the study site's standard of care. METHODS:A rando...

    journal_title:HIV clinical trials

    pub_type: 杂志文章,随机对照试验

    doi:10.1310/hct1405-235

    authors: Robbins GK,Testa MA,Su M,Safren SA,Morse G,Lammert S,Shafer RW,Reynolds NR,Chesney MA

    更新日期:2013-09-01 00:00:00

  • A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy.

    abstract:OBJECTIVE:To determine the impact of thiazolidinediones (TZD) on changes in limb fat mass in HIV-infected individuals, particularly in those not receiving a thymidine analogue. METHODS:Individual patient data from placebo-controlled, randomized trials of rosiglitazone (n = 5) or pioglitazone (n = 1) were combined. Gen...

    journal_title:HIV clinical trials

    pub_type: 杂志文章,meta分析

    doi:10.1310/hct1101-39

    authors: Raboud JM,Diong C,Carr A,Grinspoon S,Mulligan K,Sutinen J,Rozenbaum W,Cavalcanti RB,Wand H,Costagliola D,Walmsley S,Glitazone and Lipoatrophy Meta-Analysis Working Group.

    更新日期:2010-01-01 00:00:00

  • Lipid profile during pregnancy in HIV-infected women.

    abstract:PURPOSE:We investigated the evolution of serum lipid levels in HIV-infected pregnant women and the potential effect of antiretroviral treatment during pregnancy using data from a national surveillance study. METHOD:Fasting lipid measurements collected during routine care in pregnancy were used, analyzing longitudinal ...

    journal_title:HIV clinical trials

    pub_type: 杂志文章

    doi:10.1310/hct0704-184

    authors: Floridia M,Tamburrini E,Ravizza M,Tibaldi C,Ravagni Probizer MF,Anzidei G,Sansone M,Mori F,Rubino E,Meli M,Dalzero S,Guaraldi G,Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy.

    更新日期:2006-07-01 00:00:00

  • Clinical Outcomes of Virologically-Suppressed Patients with Pre-existing HIV-1 Drug Resistance Mutations Switching to Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in the SPIRIT Study.

    abstract:OBJECTIVES:Antiretroviral regimen switching may be considered for HIV-1-infected, virologically-suppressed patients to enable treatment simplification or improve tolerability, but should be guided by knowledge of pre-existing drug resistance. The current study examined the impact of pre-existing drug resistance mutatio...

    journal_title:HIV clinical trials

    pub_type: 临床试验,杂志文章

    doi:10.1080/15284336.2015.1115585

    authors: Porter DP,Toma J,Tan Y,Solberg O,Cai S,Kulkarni R,Andreatta K,Lie Y,Chuck SK,Palella F,Miller MD,White KL

    更新日期:2016-02-01 00:00:00

  • Missing scheduled visits in the outpatient clinic as a marker of short-term admissions and death.

    abstract:INTRODUCTION:It is not uncommon for patients with HIV infection to miss scheduled visits in outpatient clinics without justifying the failure to appear or reschedule the appointment. Few studies have assessed the impact of inconsistent follow-ups on resource use and disease outcomes in this patient population. OBJECTI...

    journal_title:HIV clinical trials

    pub_type: 杂志文章

    doi:10.1310/hct1305-289

    authors: Colubi MM,Pérez-Elías MJ,Elías L,Pumares M,Muriel A,Zamora AM,Casado JL,Dronda F,López D,Moreno S,SEAD Study Group.

    更新日期:2012-09-01 00:00:00

  • Virologic and immunologic response to a boosted double-protease inhibitor-based therapy in highly pretreated HIV-1-infected patients.

    abstract:PURPOSE:To assess the virologic and immunologic response to a boosted double-protease inhibitor (PI) regimen of highly pretreated patients infected with HIV-1 and to examine the role of PI resistance and concentration of serum saquinavir. METHOD:In an open-label prospective study, lopinavir/ritonavir, saquinavir-sgc, ...

    journal_title:HIV clinical trials

    pub_type: 临床试验,杂志文章

    doi:10.1310/HAG3-8YA5-UDQC-36NX

    authors: Smith GH,Boulassel MR,Klien M,Gilmore N,MacLeod J,LeBlanc R,René P,Routy JP,Lalonde RG

    更新日期:2005-03-01 00:00:00

  • Clinically stable treatment-experienced adults receiving tenofovir and didanosine.

    abstract:METHOD:Analysis of virological, immunological, and clinical data over 24 weeks of treatment of drug-experienced patients administered didanosine (ddI) and tenofovir (TDF) plus either PI or NNRTI (17 patients) compared to 14 patients on ddI plus lamivudine and to 19 patients on ddI plus stavudine. RESULTS:Patients trea...

    journal_title:HIV clinical trials

    pub_type: 临床试验,杂志文章

    doi:10.1310/0B0R-J1LP-KQPF-43HB

    authors: Di Biagio A,Beltrame A,Cenderello G,Ferrea G,De Maria A

    更新日期:2006-01-01 00:00:00

  • Immune response after a single dose of the 2010/11 trivalent, seasonal influenza vaccine in HIV-1-infected patients and healthy controls.

    abstract:BACKGROUND:Immune response rates following influenza vaccination are often lower in HIV-infected individuals. Low vitamin D levels were correlated with weak immune response in cancer patients and are known to be lower in HIV-infected patients. METHODS:Diagnostic study to determine immune response against the H1N1v com...

    journal_title:HIV clinical trials

    pub_type: 杂志文章

    doi:10.1310/hct1404-175

    authors: Bickel M,Lassmann C,Wieters I,Doerr HW,Herrmann E,Wicker S,Brodt HR,Stephan C,Allwinn R,Jung O

    更新日期:2013-07-01 00:00:00

  • Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients.

    abstract:PURPOSE:The objectives of this study were to determine the prevalence of osteopenia and the factors associated with its presence in HIV-infected patients under highly active antiretroviral therapy (HAART) and to assess the changes of bone mineral density (BMD) in a population followed prospectively. METHOD:BMD was ass...

    journal_title:HIV clinical trials

    pub_type: 杂志文章

    doi:10.1310/4X0H-UVMJ-BHYW-CPFB

    authors: Fernández-Rivera J,García R,Lozano F,Macías J,García-García JA,Mira JA,Corzo JE,Gómez-Mateos J,Rueda A,Sánchez-Burson J,Pineda JA

    更新日期:2003-09-01 00:00:00

  • Tuberculosis and HIV infection: epidemiology, immunology, and treatment.

    abstract::Tuberculosis and HIV have combined to present a major threat to global public health. Each disease has a negative effect on the other, and mortality in patients with both tuberculosis and HIV is higher than that caused by either condition alone. In regions such as sub-Saharan Africa, as many as a third or more of all ...

    journal_title:HIV clinical trials

    pub_type: 杂志文章,评审

    doi:10.1310/TUNH-UAKU-N0E4-1PXF

    authors: Schluger NW,Burzynski J

    更新日期:2001-07-01 00:00:00

  • Failure to identify HIV-infected individuals in a clinical trial using a single HIV rapid test for screening.

    abstract:BACKGROUND:In the HIV Prevention Trials Network (HPTN) 061 study, 8 (2.3%) of 348 HIV-infected participants identified as HIV uninfected at study enrollment using a single HIV rapid test for screening were found to be HIV infected after additional testing. OBJECTIVES:To evaluate the performance of different HIV assays...

    journal_title:HIV clinical trials

    pub_type: 临床试验,杂志文章

    doi:10.1310/hct1502-62

    authors: Piwowar-Manning E,Fogel JM,Laeyendecker O,Wolf S,Cummings V,Marzinke MA,Clarke W,Breaud A,Wendel S,Wang L,Swanson P,Hackett J Jr,Mannheimer S,Del Rio C,Kuo I,Harawa NT,Koblin BA,Moore R,Blankson JN,Eshleman SH

    更新日期:2014-03-01 00:00:00

  • Granulocyte-macrophage colony-stimulating factor (GM-CSF) restores allostimulatory function to accessory cells in patients with AIDS.

    abstract:BACKGROUND:Impaired allostimulatory function of dendritic cells in patients with AIDS has been reported previously. Granulocyte-macrophage colony-stimulating factor (GM-CSF) can restore the T-cell stimulatory function in transforming growth factor-beta 1 (TGF-beta 1)-inhibited murine accessory cells. We now report the ...

    journal_title:HIV clinical trials

    pub_type: 临床试验,杂志文章

    doi:10.1310/HP8B-NF27-VFWA-80YX

    authors: Bernstein ZP,Brooks SP,Chanan-Khan A,Gollnick SO,Gilbert MJ,Miller KC,Tomasi TB

    更新日期:2002-05-01 00:00:00

  • Salvage therapy with amprenavir and ritonavir: prospective study in 17 heavily pretreated patients.

    abstract:OBJECTIVE:To evaluate the safety profile and efficacy of salvage regimens containing amprenavir (APV) 600 mg twice daily and ritonavir (RTV) 200 mg twice daily. DESIGN:Prospective, single-center study. METHOD:The patient database of the department of infectious diseases was screened for patients who had failed at lea...

    journal_title:HIV clinical trials

    pub_type: 临床试验,杂志文章

    doi:10.1310/RFT5-7N0M-8C5G-0TL2

    authors: Arvieux C,Tattevin P,Souala FM,Jaccard P,Ruffault A,Bentué-Ferrer D,Tribut O,Chapplain JM,Dupont M,Bouvier C,Michelet C

    更新日期:2002-03-01 00:00:00

  • Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection.

    abstract:PURPOSE:Selecting the optimal treatment regimen for antiviral-naive patients may be difficult, given the concern about the antiviral activity, the development of drug resistance, and the increase in drug costs. This study evaluates the costs and effectiveness of using lopinavir/ritonavir (LPV/r) vs. nelfinavir (NFV), b...

    journal_title:HIV clinical trials

    pub_type: 杂志文章

    doi:10.1310/WT81-MEM4-5C4L-CHPK

    authors: Simpson KN,Luo MP,Chumney E,Sun E,Brun S,Ashraf T

    更新日期:2004-09-01 00:00:00

  • Long-term outcome of HIV-infected patients with multinucleoside-resistant genotypes.

    abstract:BACKGROUND:Multiple resistance to nucleoside analogs mediated by the Q151M complex and/or codon 67-69 inserts/deletions represents a growing problem among HIV-infected persons, most of whom have been exposed to sequential therapies for long periods of time. PATIENTS AND METHOD:All plasma samples collected from HIV-inf...

    journal_title:HIV clinical trials

    pub_type: 杂志文章

    doi:10.1310/X618-KWKJ-WCTQ-LQ2L

    authors: Gallego O,d Mendoza C,Labarga P,Altisent C,González J,García-Alcalde I,Valer L,Valencia E,Soriano V

    更新日期:2003-11-01 00:00:00

  • Improved survival in HIV-associated diffuse large B-cell lymphoma with the addition of rituximab to chemotherapy in patients receiving highly active antiretroviral therapy.

    abstract:PURPOSE:Recent trials suggest serious toxicity in HIV-associated non-Hodgkin's lymphoma (NHL) with rituximab (R) and chemotherapy (CT), offsetting the benefit of rituximab. METHOD:We retrospectively reviewed experience with CHOP-R vs. CT in 40 patients with HIV-associated diffuse large B-cell lymphoma (DLBCL) diagnose...

    journal_title:HIV clinical trials

    pub_type: 杂志文章

    doi:10.1310/hct0803-132

    authors: Ezzat H,Filipenko D,Vickars L,Galbraith P,Li C,Murphy K,Montaner JS,Harris M,Hogg RS,Vercauteren S,Leger CS,Zypchen L,Leitch HA

    更新日期:2007-05-01 00:00:00

  • HIV production from purified monocytes isolated from antiretroviral-naïve and protease inhibitor-treated HIV-1-infected patients.

    abstract:PURPOSE:We obtained peripheral blood monocytes from HIV-1-infected patients and differentiated them into macrophages in vitro to investigate the contribution of purified monocytes to plasma viremia in HIV-infected patients. METHOD:We compared the production of HIV-1 from purified monocytes isolated from patients who w...

    journal_title:HIV clinical trials

    pub_type: 杂志文章

    doi:10.1310/EF26-V3PC-AG5X-FCF4

    authors: Kazanjian P,Adams D,Tate S,Newman G

    更新日期:2002-11-01 00:00:00

  • Sustained efficacy of nevirapine in combination with two nucleoside analogues in the treatment of HIV-infected patients: a 48-week retrospective multicenter study.

    abstract:BACKGROUND:Nevirapine, a nonnucleoside analogue, has demonstrated suppression of human immunodeficiency virus (HIV) replication alone and in combination therapy. However, the durable suppression of HIV with nevirapine when used along with other nucleosides in HIV-infected patients who are treated in clinical practice n...

    journal_title:HIV clinical trials

    pub_type: 杂志文章,多中心研究

    doi:10.1310/4nb4-1gx6-4xvk-pbgl

    authors: Allan PS,Arumainayagam J,Harindra V,Tobin J,Browning M,Yoganathan K,Wade A,Das S

    更新日期:2003-07-01 00:00:00

  • Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir+ritonavir+emtricitabine/tenofovir DF in antiretroviral-naïve patients.

    abstract:OBJECTIVE:To describe baseline and emergent HIV-1 resistance to elvitegravir/ cobicistat/emtricitabine/tenofovir DF (EVG/COBI/FTC/TDF) and ritonavir-boosted atazanavir/emtricitabine/tenofovir DF (ATV+RTV+FTC/TDF) in HIV-1-infected, treatment-naïve subjects through 144 weeks. METHOD:This was a randomized, double-blind,...

    journal_title:HIV clinical trials

    pub_type: 杂志文章,随机对照试验

    doi:10.1310/hct1505-218

    authors: Kulkarni R,Abram ME,McColl DJ,Barnes T,Fordyce MW,Szwarcberg J,Cheng AK,Miller MD,White KL

    更新日期:2014-09-01 00:00:00

  • Efficacy and safety of stavudine plus didanosine in asymptomatic HIV-infected children with plasma HIV RNA below 50,000 copies per milliliter.

    abstract:BACKGROUND:Simple antiretroviral drug combinations might provide a comparable benefit to standard triple regimens in patients with mild HIV disease, because poor adherence and toxicities often compromise the sustained benefit of the latest triple regimens, especially when protease inhibitors are used. Bad adherence is ...

    journal_title:HIV clinical trials

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1310/FAJF-7A8G-QAR4-Q0X5

    authors: de Mendoza C,Ramos JT,Ciria L,Fortuny C,García FJ,de José MI,Asensi F,Soriano V

    更新日期:2002-01-01 00:00:00

  • Serious renal impairment occurs rarely with use of tenofovir DF.

    abstract:PURPOSE:The purpose of this study was to evaluate the short-term effects (up to 6 months) of tenofovir disoproxil fumarate (DF) use on renal function in patients being treated for HIV-1 infection. METHOD:The charts of 447 HIV-1-infected patients who received at least three months of tenofovir DF treatment were reviewe...

    journal_title:HIV clinical trials

    pub_type: 杂志文章,多中心研究

    doi:10.1310/2taj-qpd1-tyae-qak5

    authors: Scott JD,Wolfe PR,Bolan RK,Guyer B

    更新日期:2006-03-01 00:00:00

  • The 2004 International AIDS Conference and how to globally counter HIV/AIDS.

    abstract::This article reports noteworthy HIV/AIDS clinical trials presented at the XVth International AIDS Conference, Bangkok, July 2004, and also outlines goals of comprehensive prevention, care, treatment, and monitoring plans. The Bangkok conference theme was "Access for All." Outlined are goals of comprehensive prevention...

    journal_title:HIV clinical trials

    pub_type:

    doi:10.1310/RM35-RE2A-J9L2-8J47

    authors: Idemyor V

    更新日期:2005-01-01 00:00:00

  • Evolution of genotypic resistance algorithms and their impact on the interpretation of clinical trials: an OPTIMA trial substudy.

    abstract:PURPOSE:The outdated rules of older HIV genotypic resistance algorithms can affect virologic responses. This study was designed to determine how often these incorrect resistance interpretations affect analyses of long-term clinical trials, antiretroviral (ARV) choices, and HIV disease progression rates. METHOD:Baselin...

    journal_title:HIV clinical trials

    pub_type: 杂志文章

    doi:10.1310/hct0805-293

    authors: Desai S,Kyriakides T,Holodniy M,Al-Salman J,Griffith B,Kozal M

    更新日期:2007-09-01 00:00:00